Since the development of techniques for the isolation of individual cells from the liver, transplantation of isolated hepatocytes has been considered a potential therapy for the treatment of liver disorders. Over the last several decades, laboratories have progressively shown that primary hepatocytes can engraft in the liver, spleen, peritoneal cavity, and other extrahepatic sites, and can function following transplantation to correct liver-based errors of metabolism and prolong the survival of animals with liver failure.
Introduction
Since the development of techniques for the isolation of individual cells from the liver, transplantation of isolated hepatocytes has been considered a potential therapy for the treatment of liver disorders. Over the last several decades, laboratories have progressively shown that primary hepatocytes can engraft in the liver, spleen, peritoneal cavity, and other extrahepatic sites, and can function following transplantation to correct liver-based errors of metabolism and prolong the survival of animals with liver failure.
Liver cell transplantation (LCT) presents distinct advantages over orthotopic liver transplantation (OLT) for organ replacement therapy: LCT is technically simpler than OLT, requiring only injection/infusion of a cell suspension; hepatocytes can be cryopreserved for future use; and hepatocytes obtained from one donor can be used for multiple patients. Yet, major obstacles to the broad clinical use of LCT include the competition with OLT for the few suitable donor livers, long-term cell engraftment and function, effective and adequate immunosuppressant protocols, and the fact that primary hepatocytes cannot be readily expanded in vitro.
As the host liver and its vasculature remain intact, the consequences of graft loss would be relatively small. LCT could effectively replace whole organ transplantation for the treatment of many inherited disorders of metabolism if an enhanced and facilitated donor cell repopulation could be achieved; hence, transplantation of a relatively small number of liver cells, representing only a fraction of the liver mass, could be used to avoid removing an otherwise normally functioning native liver.
A number of studies have been published demonstrating that stem/progenitor cells can be differentiated toward 'hepatocyte-like cells', a term that has been used to describe cells generated in vitro that show some characteristics of mature hepatocytes but still are not fully mature and/or characterized. However, it is currently impractical to determine which is the most suitable stem/progenitor population to repopulate the liver. At this point, the differences in the starting cell population, differentiation protocols, and most importantly the assays performed to assess differentiation and endpoints of preclinical transplantation studies have limited the criteria standardization of the term and minimal characterization of stem/progenitor cell populations that are the best for the therapy of a given liver disease.
Current clinical liver cell transplantation
So far, human LCT has been attempted in patients with acute liver failure, in chronic liver disease with cirrhosis, and in children with liver-based metabolic disease. To date, data concerning the efficacy of LCT for hepatic failure in humans have been difficult to interpret, and although clinical experiences lack the impressive stimulation of regeneration found in animal experiments, LCT remains an alternative experimental treatment to bridge patients to orthotopic transplantation or auxiliary partial orthotopic liver transplantation (APOLT) with the purpose to reduce the risk related to liver transplantation in patients with clinical complications.
Human liver cell transplantation in metabolic liver disease
Allogenic LCT has been reported in patients to correct a variety of metabolic disorders including ornithine transcarbamylase (OTC) deficiency [1-3,4 ,5,6], alpha-1-antitrypsin deficiency [7, 8] , glycogen storage disease type 1a [9] , infantile Réfsum's disease [10] , factor VII deficiency [11] , bile salt export protein deficiency (PFIC2) [8] , and Crigler-Najjar syndrome type 1 [12] [13] [14] [15] . The efficacy of LCT as a bridge to subsequent APOLT has recently been demonstrated in a newborn with OTC deficiency [4 ] . This report demonstrated that LCT should be considered effective as a bridge to liver transplantation in OTC deficiency to improve growth and neurodevelopmental outcomes.
With respect to long-term engraftment, it will be important whether the transplanted hepatocytes will gain a selection advantage over the recipient's cells. Therefore, it could be reasonable to differentiate between two groups of metabolic liver diseases. A typical representative of group 1 is inherited clotting factor deficiencies. Secretion of clotting factors is important for the organism, but deficiency does not influence survival of hepatocytes. Therefore, a selection advantage of the transplanted hepatocytes cannot be expected. The situation is different for group 2 metabolic liver diseases. A typical example is Wilson's disease that is caused by a defect in the copper transporting ATPase ATP7B protein. As a consequence of the gene defect, copper will accumulate and lead to deterioration of hepatocytes [16] . In this case, transplanted wild-type cells may have a selection advantage over the recipient's hepatocytes. Therefore, higher numbers of transplanted hepatocytes, better cell engraftment, and perhaps repeated transplantations may be necessary for the treatment of group 1 metabolic liver diseases. However, clinical data with respect to possible differences in long-term engraft between group 1 and 2 are not yet available.
Human liver cell transplantation in chronic liver failure Cell therapy of end-stage liver disease is more problematic. In addition to loss of functional hepatocytes, abnormalities of the hepatic architecture contribute to the decrease in liver function. In this situation, the benefit of additionally transplanted hepatocytes into the liver without restoring the normal liver architecture may be questionable.
The response to hepatocyte transplantation in humans with end-stage liver disease has not resulted in the same degree of improvement as seen in experimental animal studies [7, 17] . One explanation may be that the hepatocytes in clinical studies were delivered into the splenic artery and not into the splenic pulp. It has been shown that the route of hepatocyte delivery influences hepatocyte engraftment and function [18] .
In the USA, eight patients with decompensated chronic liver disease have been treated by transplantation with up to 10 10 liver cells through the splenic artery. One of the three patients who was a candidate for organ transplantation was successfully transplanted. In two patients, scanning for transplanted hepatocytes using uptake of glycosylated albumin with 99mTc indicated the presence of engrafted hepatocytes in the spleen [7] . One patient with hepatitis C virus (HCV) cirrhosis had histologic evidence of transplanted hepatocytes forming cordlike structures with normal tight cellular junctions in the spleen by day 2 postinfusion [19] . In three children, single hepatocyte administrations by transfemoral intraarterial splenic infusion or transhepatic and transjugular portal venous infusion led to clinically significant ammonia and encephalopathy control for up to 6 weeks and to successful bridging to liver transplant and full recovery in two of the three [20] . Recently, a girl of 1 year of age with biliary atresia, as evidenced by a bilirubin of 28.4 mg/dl, was treated with hepatic progenitor cell infusion through the hepatic artery [21] . A catheter was manipulated into the portal vein and 4 Â 10 6 cells/ml in a total of 3 ml volume of progenitor cells were infused. The total bilirubin and conjugated bilirubin started decreasing during the first month after cell infusion. The conjugated bilirubin was 16.35 mg/dl before cell infusion, decreasing to eight-fold after cell infusion. After 2 months of cell infusion, hepatobiliary scintigraphy showed increased liver cell function [21] . The same group conducted autologous transplantation of mesenchymal stem cells (MSCs; CD34 þ cells) in four patients with chronic liver failure; however, clear benefit could not be demonstrated from the cell transplantation procedure [22] .
Human liver cell transplantation in acute liver failure Acute liver failure is characterized by rapid deterioration of liver function and a high mortality [23] . Viral hepatitis, idiosyncratic drug reactions, acetaminophen, and mushroom ingestion are common causes of acute liver failure. Hepatic encephalopathy, brain edema, coagulopathy, septicemia, and multiorgan failure are critical key events [23, 24] during the course of the disease.
LCT of acute liver failure should provide rapid support for the failing liver by providing metabolism of liver toxins, the secretion of proteins such as clotting factors or albumin, and stabilization of hemodynamic parameters. In several studies, allogeneic primary hepatocytes isolated from cadaver livers were infused into the splenic artery, the portal vein, and intraperitoneal cavity [7, 20, [25] [26] [27] [28] [29] [30] . Improvements in ammonia levels, encephalopathy scores, and prothrombin time levels were reported.
More than a dozen children, aged between 3.5 months and 16 years, have been treated with intraportal and intraperitoneal (one patient) hepatocyte infusions, under conventional immunosuppression, for drug, idiopathic or viral acute liver failure; about 20% patients experienced full recovery without solid organ transplant, and about 30% children were successfully bridged to OLT with full recovery [7, 26, 27] .
Despite the positive results, it should be considered that the evaluation of therapies in acute liver failure might be difficult. This is due to large variations in the course of the disease, multiple causes, complex supportive treatment, and a spontaneous recovery rate of approximately 20% by successful hepatic self-regeneration [23] . Thus, the inclusion of adequate controls is difficult. In this respect, studies on patients with inherited metabolic diseases are easier to interpret. Although there is some suggestion that the transplanted hepatocytes provided a benefit, convincing evidence for engraftment and function of the transplanted cells has not been obtained. Part of the problem could be that a relatively small number of liver cells were transplanted in many of the patients.
Unfortunately, a large number of issues will need to be addressed before this technology can be applied to the large number of patients who could potentially benefit from it.
Conditions for liver repopulation
Although in-vitro tests may suggest hepatocyte-like cells characterization, the ultimate proof to demonstrate that differentiation has been achieved is to show that the differentiated cell can repopulate the liver and restore liver function in a preclinical model of liver disease. There is enough evidence suggesting that the injured hepatic microenvironment may induce further maturation of partially differentiated cells [31 , [32] [33] [34] [35] [36] (a brief and concise review [34] that describes origin and end of hepatocytes and the multiple sources of hepatocytes).
Following infusion into the portal circulation or implantation into the spleen, the vast majority of donor liver cells translocate to the liver and accumulate in the hepatic sinusoids, causing transient portal hypertension that resolves in hours [37, 38] (Fig. 1) .
Investigators have shown that immediately after injection into the spleen or portal vein, transplanted hepatocytes are deposited in the portal region and the sinusoidal spaces. However, the capacity of the sinusoidal spaces limits the number of hepatocytes that can be transplanted. It has been estimated that, at any one time, hepatocytes equivalent to up to 10% of the liver mass can be transplanted into livers with normal architecture without long-term deleterious effects [18, 39, 40] . Studies indicate that less than 30% of transplanted hepatocytes survive in the liver, although the number of surviving cells increases as more hepatocytes are transplanted [37, 41, 42] (Fig. 1) .
Passage of hepatocytes into the space of Disse requires retraction of the sinusoidal endothelial cells (SECs). Shortly after entering the space of Disse, there is a transient disruption of the gap junction and tight junction between adjacent hepatocytes in the vicinity of the transplanted hepatocytes. The transplanted cells then insert themselves between host hepatocytes. Pharmacologic disruption of endothelial integrity and sinusoidal dilatation appear to improve engraftment [37, 38] . Hepatic nonparenchymal cells are major modulators of initial hepatocyte engraftment. First, the hepatic SECs pose a physical barrier to the passage of the transplanted hepatocytes into the space of Disse and second, Kupffer cells and probably other inflammation-mediating cells may clear the transplanted cells, reducing the number of hepatocytes available for engraftment. Now, integration and proliferation of transplanted liver cells requires space, for instance, partial hepatectomy or hepatocyte necrosis and/or apoptosis, and the transplanted cells have a growth advantage over endogenous hepatocytes. Several laboratories have developed strategies to induce preferential proliferation of engrafted hepatocytes. These approaches have led to massive repopulation of transplanted primary hepatocytes. This has been achieved by preparatively treating rodent hosts with retrorsine or lasiocarpine, which are pyrrolizidine alkaloids that induce a long-lasting cell cycle block, and two-thirds hepatectomy, which provides a strong mitotic stimulus to hepatocytes. An alternative approach that consists of preparative hepatic irradiation has been suggested, which reduces mitotic capacity of the host hepatocytes [43 ,44 ] .
Even though hepatocyte-like cells generated from stem/ progenitor cells may yield some levels of engraftment, these levels fall far short of those seen when mature or fetal hepatocytes are engrafted [44 ,45 ] . The reasons underlying the poor performance of stem/progenitorderived cells compared with primary liver-derived cells when engrafted into the liver are unknown.
The rules governing parenchymal repopulation by hepatocytes are likely to be similar for hepatocyte-like cells generated from stem/progenitor cells. However, a number of differences between mature hepatocytes and stem/ progenitor-derived hepatocyte-like cells may explain the differential degree of liver repopulation. For instance, mature cells are of relatively larger size compared with stem/progenitor-derived hepatocyte-like cells, which may cause cell retention within the sinusoids. Signals that govern this process when stem/progenitor cell-derived hepatocytes are grafted remain to be determined. It is also not known whether stem/progenitor cell-derived hepatocytes may have a proliferative disadvantage over mature hepatocytes that have extensive proliferation potential [46] and/or may undergo significantly more apoptosis when grafted.
Cells with liver repopulation capacities
After partial hepatectomy, the excised liver lobes never grow back, but the remaining lobes grow to compensate for the mass of the tissue. Mature cell types mediate reconstitution of the entire liver mass, which is complete within 7 days in rodents. The most important signals are hepatocyte growth factor, interleukin-6, tumor necrosis factor, transforming growth factor, and epidermal growth factor [47 ] . A small amount of information is known about how liver regeneration is terminated once the appropriate liver mass is restored. However, the exogenous factors (endocrine, paracrine, or autocrine) that sense overall liver size are yet not known; even though several intracellular signals have been identified. For instance, some evidence suggests that transforming growth factor beta-1 is important in termination of liver regeneration [48 ] . Recent work strongly implicates the detection of blood bile acid levels by nuclear receptors, including farnesoid X receptor (FXR), as a regulator of liver growth [49] .
Hepatocytes themselves have high capacity for liver repopulation. Recently, Azuma et al. [46] generated severely immunodeficient, fumarylacetoacetate hydrolase (Fah)-deficient mice. After pretreatment with a urokinase-expressing adenovirus, these animals could be highly engrafted (up to 90%) with human hepatocytes from multiple sources, including liver biopsies. Furthermore, human cells could be serially transplanted from primary donors and repopulate the liver for at least four sequential rounds. Notably, this massive cell repopulation has not been documented in humans.
Liver repopulation by adult stem cells
Liver regeneration capacity results mainly from mitotic division of mature hepatocytes, bile duct, and endothelial cells. But under special circumstances, hepatic progenitors called oval cells are activated to expand and take part in liver regeneration when the proliferative capacity of the mature native hepatocytes is impaired and a stimulus of regeneration is present [34] . Hepatic oval cells express markers associated with immature liver cells, such as alphafetoprotein; mature hepatocytes, such as albumin; and hematopoietic stem cell, such as c-kit, Thy-1, CD34 and Sca-1 [34] . These bipotential progenitors, isolated from the liver, differentiate into mature hepatocytes after transplantation into the liver [34] . However, currently, it is uncertain whether such cells can be maintained and expanded in vitro to be used in lieu of adult hepatocytes for clinical application and its contribution to carcinogenesis is not yet clear. Nonetheless, oval cells isolated from the adult liver represent a promising source for cellbased therapy.
Bone marrow cells are an attractive source for extrahepatic stem cells. Hepatocytes can, in fact, be generated from hematopoietic stem cells and the mechanism by which hematopoietic cells can directly affect hepatic regeneration includes both transdifferentiation and fusion of a cell of hematopoietic origin with defective hepatocytes [32] [33] [34] . Their capacity to integrate into injured livers of animals has been reported to be low and the clinical potential to correct liver disease remains to be determined from either bone marrow or adipose tissue MSCs [50] . Another mechanism reported to alleviate liver injury using MSCs is the secretion of soluble factors. Recent studies directed by our group have found that injection of conditioned medium from MSCs or the use of a liver-assist device can reduce hepatocyte death and increase hepatocyte replication [51 ,52 ] . However, the exact mechanism and the type of liver injury that can be treated by this strategy remain to be determined.
Liver repopulation by liver fetal progenitor cells
Fetal human liver progenitor cells have shown enormous replication and differentiation potential, including the capacity to generate mature hepatocytes after transplantation in immunodeficient animals [53] mainly due to the extended reconstitution of telomerase activity, which maintains chromosomal integrity during cell division even after cryopreservation [54] . Oertel et al. have used fetal rat liver cells to show at least three distinct subpopulations of hepatoblasts exist between embryonic days 12 and 14. Based on histochemical markers, one population appeared to be bipotential and the other two harbored either unipotent hepatocyte or biliary epithelial cell phenotypes.
The same group has reported that a phenomenon known as cell competition is responsible for the liver repopulation, in which the transplanted fetal liver cells are capable of repopulating the liver by inducing apoptosis in neighboring host hepatocytes that proliferate more slowly than the transplanted cells [55] . Thus, if the engrafted hepatocytes possess a greater proliferative capacity than the host hepatocytes, the engrafted cells would grow preferentially in response to mitotic stimuli, progressively competing out the host hepatocytes [16] . Nevertheless, the supply of fetal human tissues is also not unlimited and the possibility of oncogenic perturbations needs further study. Moreover, it will be important to determine whether cells derived from fetal livers before 20 weeks of gestational age, when most elective abortions are performed, would express differentiated hepatocellular function after transplantation [56] . Clinical transplan-tation of fetal hepatocytes in patients with acute liver failure has been documented but resulted in modest clinical improvement in hepatic coma [27] , but further studies need to be performed to corroborate clinical significance.
Liver repopulation by pluripotent stem-derived hepatic cells
At this point, most published embryonic stem cells differentiation protocols that generate hepatocyte-like cells have reported in general a limited functionality and not complete maturity. Major liver repopulation has been difficult to document. However, it has been reported that by selecting for cells expressing markers such as the asialoglycoprotein receptor, it is possible to isolate the most hepatocyte-like cells in the culture with repopulating capacity [44 ] . It appears likely that conditions and protocols will be developed for the practical production of embryonic stem cell-derived hepatocytes. Nevertheless, major advances have been difficult to achieve. The development of induced pluripotent stem (iPS) cells from adult somatic tissue [57 ] may provide major advantages over the development of hepatocytelike cells. Confirmation that iPS cells have hepatocytelineage differentiation capacity comparable to that of existing differentiated embryonic stem cells needs to be studied. Nevertheless, iPS-derived hepatocytes are a very promising population for future therapeutic transplantation.
Future perspectives on liver repopulation
In future studies, clinical investigators, cell biologists, and bioengineers will need to investigate together several issues that remain uncertain to date. For instance, the optimal hepatic differentiation level that is required to achieve high levels of liver repopulation and function is unknown. Long-term studies after transplantation of hepatocytes derived from stem/progenitor cells are required to elucidate any adverse effects.
Integration of technologies derived from tissue engineering and liver development would be of great promise. The liver extracellular matrix (ECM) presents an ideal scaffold for stem cell differentiation into hepatocytes, as well as cell transplantation. It is known that local environmental factors induce hepatocyte homing, differentiation, and proliferation, and studies indicate that stem cells may differentiate toward mature hepatocytes following transfer into injured liver [58 ] . It is reasonable to expect that a similar beneficial response will be observed for liver grafts as well. Thus, new techniques for decellularization of liver matrix [59 ] present great potential as the scaffold for hepatocyte maturation and transplantation. This process may be further manipulated by sequential delivery of factors involved in the initiation and maturation of stem cells to liver cells, allowing temporal and spatial control over differentiation.
The evidence reviewed here strongly supports the conclusion that the realization of cell transplantation methods would be much enhanced with the engineering of an ideal transplantable scaffold. This scaffold would provide all the necessary microstructure and extracellular cues for cell attachment, differentiation, functioning, vascularization and the necessary space for repopulation with liver cells derived from stem cells [60 ]. One exciting possibility is the utilization of decellularized liver extracellular matrix as the scaffold for cell transplantation, which could ultimately allow the development of engineered auxiliary liver grafts for transplantation and open the doors to a new era of organ engineering.
Conclusion
Whether stem cell-derived liver cells will soon be available to treat liver disease is not known. Although there are many promising laboratory studies, only a handful of disease models have been examined concerning whether stem cells can correct liver disease. Thus, normal liver turnover, regeneration after injury, or repopulation following transplantation is mediated differently depending on the precise circumstances and cell type. It is premature to conclude that hepatocytes can be generated from nonhepatic cells in culture that will be clinically useful. Standard criteria will need to be developed to assess the extent to which human stem cell-derived hepatocytes have been produced. To date, there are more questions than answers and several points must be addressed before stem/progenitor cells capable of generating hepatocyte-like cells can be translated into successful clinical therapies.
